Halozyme Therapeutics | HALO - EPS Earnings Per Share


Halozyme Therapeutics reported $1.6 in EPS Earnings Per Share for its fiscal quarter ending in March of 2026.


Fiscal Calendar Actual Consensus Previous Date
FY2026Q3 Sep/2025 2.18 1.72 Nov/09
FY2026Q2 Jun/2026 1.81 1.54 Aug/11
FY2026Q1 Mar/2026 1.60 1.76 1.11 May/11
FY2025Q4 Dec/2025 -0.24 1.9 1.26 Feb/17
FY2025Q3 Sep/2025 1.72 1.59 1.27 Nov/03




Eps Change Date
Acadia Pharmaceuticals USD 0.02 1.58 Mar/2026
Agios Pharmaceuticals USD -1.69 0.17 Mar/2026
Alnylam Pharmaceuticals USD 1.99 0.74 Mar/2026
Amarin USD 0.14 0.06 Dec/2025
Amgen USD 5.15 0.14 Mar/2026
Baxter International USD 0.36 0.08 Mar/2026
Cara Therapeutics USD -0.59 4.45 Sep/2025
Cytokinetics USD -1.67 0.17 Mar/2026
DBV Technologies USD -0.55 0.31 Mar/2026
Eli Lilly USD 8.55 1.01 Mar/2026
Halozyme Therapeutics USD 1.6 1.84 Mar/2026
Intrexon USD -0.1 0.03 Jun/2024
Ionis Pharmaceuticals USD -0.56 0.85 Mar/2026
MannKind USD -0.02 0.03 Mar/2026
Minerva Neurosciences USD -0.56 3.53 Dec/2024
Nektar Therapeutics USD -1.35 1.17 Dec/2025
Pfizer USD 0.75 0.09 Mar/2026
Rigel Pharmaceuticals USD 0.7 0.76 Sep/2024
United Therapeutics USD 5.82 1.88 Mar/2026
Vanda Pharmaceuticals USD -0.09 0 Dec/2024